Reviewer's report

Title: Late Presentation of Sorafenib-Associated Rash: Case Report and Review of the Literature

Version: 2 Date: 10 March 2010

Reviewer: Carlo Buonerba

Which of the following best describes what type of case report this is?: Unreported or unusual side effects or adverse interactions involving medications

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: No

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: No

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: No

Is the anonymity of the patient protected?: Yes

Comments to authors:

Sarkodie and Ross present the case of a HCC patient who reported a stable disease for a considerably long period (3 years), with late onset of a recurrent, treatment-related rash.

This report is interesting and very well written, and my few comments are minor.

1) Timing of rash onsets and sorafenib administration should be summarized in a graph, with time on the x axis and vertical arrows to indicate time of rash and treatment, in order to give a visual impact of periods on and off therapy.

2) Given the long period of treatment, at least two CT scans (an initial and a final one) could be helpful to the reader.
3) Discussion is focused on the rash. It should be underlined that this rash marginally affected treatment outcome and that intermittent therapy with sorafenib could be tested as a clinical option to minimize sorafenib toxicity. Although my main field of interest is brain and genitourinary cancer, I had a similar case myself, who benefited from prolonged treatment and treatment suspensions, while preserving stable disease.

4) In case presentation, 'become pustular' should read, 'and became pustular'.

In conclusion, this report is complete and well written, but authors could take advantage of this case to speculate a little more on the potential clinical and experimental implications of this case.

**Quality of written English:** Acceptable

**Declaration of competing interests:**

I declare that I have no competing interests